Vasoactive intestinal peptide as a new drug for treatment of primary pulmonary hypertension
AUTOR(ES)
Petkov, Ventzislav
FONTE
American Society for Clinical Investigation
RESUMO
Primary pulmonary hypertension is a fatal disease causing progressive right heart failure within 3 years after diagnosis. We describe a new concept for treatment of the disease using vasoactive intestinal peptide, a neuropeptide primarily functioning as a neurotransmitter that acts as a potent systemic and pulmonary vasodilator. Our rationale is based on the finding of a deficiency of the peptide in serum and lung tissue of patients with primary pulmonary hypertension, as evidenced by radioimmunoassay and immunohistochemistry. The relevance of this finding is underlined by an upregulation of corresponding receptor sites as shown by Northern blot analysis, Western blot analysis, and immunological techniques. Consequently, the substitution with the hormone results in substantial improvement of hemodynamic and prognostic parameters of the disease without side effects. It decreased the mean pulmonary artery pressure in our eight study patients, increased cardiac output, and mixed venous oxygen saturation. Our data provide enough proof for further investigation of vasoactive intestinal peptide and its role in primary pulmonary hypertension.
ACESSO AO ARTIGO
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=154449Documentos Relacionados
- Pulmonary clearance of vasoactive intestinal peptide.
- Emerging roles of vasoactive intestinal peptide: a new approach for autoimmune therapy
- Captopril as treatment for patients with pulmonary hypertension. Problem of variability in assessing chronic drug treatment.
- The treatment of primary pulmonary hypertension.
- Diazoxide in treatment of primary pulmonary hypertension.